+

WO2000053191A3 - Modulation de l'activation du precurseur du muscle squelettique - Google Patents

Modulation de l'activation du precurseur du muscle squelettique Download PDF

Info

Publication number
WO2000053191A3
WO2000053191A3 PCT/CA2000/000255 CA0000255W WO0053191A3 WO 2000053191 A3 WO2000053191 A3 WO 2000053191A3 CA 0000255 W CA0000255 W CA 0000255W WO 0053191 A3 WO0053191 A3 WO 0053191A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal muscle
muscle precursor
modulation
cell activation
precursor cell
Prior art date
Application number
PCT/CA2000/000255
Other languages
English (en)
Other versions
WO2000053191A2 (fr
Inventor
Judy E Anderson
Original Assignee
Univ Manitoba
Judy E Anderson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba, Judy E Anderson filed Critical Univ Manitoba
Priority to CA002371927A priority Critical patent/CA2371927A1/fr
Priority to AU31395/00A priority patent/AU3139500A/en
Priority to US09/936,609 priority patent/US6967102B1/en
Publication of WO2000053191A2 publication Critical patent/WO2000053191A2/fr
Publication of WO2000053191A3 publication Critical patent/WO2000053191A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes, des compositions pharmaceutiques et des trousses permettant de moduler l'activation du précurseur du muscle squelettique. Pour effectuer cette modulation, on utilise du monoxyde d'azote (NO), des donneurs de NO, des inhibiteurs d'activité du NO (inhibiteurs de NO) ou des régulateurs de production de NO, soit au niveau local, soit au niveau systémique. L'invention concerne également l'utilisation de NO, d'un donneur de NO, d'un inhibiteur de NO ou d'un régulateur de production de NO afin de moduler les effets des stéroïdes hormonaux sur le muscle squelettique. L'invention concerne également une méthode permettant d'identifier un composé qui provoque un changement de l'état d'activation des précurseurs du muscle. L'invention apporte un certain nombre d'avantages évidents. En permettant de manipuler directement les précurseurs du muscle squelettique, l'invention permet d'élaborer des traitements spécifiques afin de régénérer et de réparer le muscle.
PCT/CA2000/000255 1999-03-11 2000-03-10 Modulation de l'activation du precurseur du muscle squelettique WO2000053191A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002371927A CA2371927A1 (fr) 1999-03-11 2000-03-10 Manipulation par l'oxide nitrique de l'activation de cellule satellite musculaire
AU31395/00A AU3139500A (en) 1999-03-11 2000-03-10 Modulation of skeletal muscle precursor cell activation
US09/936,609 US6967102B1 (en) 1999-03-11 2000-03-10 Nitric oxide manipulation of muscle satellite cell activation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12389599P 1999-03-11 1999-03-11
US60/123,895 1999-03-11

Publications (2)

Publication Number Publication Date
WO2000053191A2 WO2000053191A2 (fr) 2000-09-14
WO2000053191A3 true WO2000053191A3 (fr) 2001-09-13

Family

ID=22411541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000255 WO2000053191A2 (fr) 1999-03-11 2000-03-10 Modulation de l'activation du precurseur du muscle squelettique

Country Status (3)

Country Link
AU (1) AU3139500A (fr)
CA (1) CA2371927A1 (fr)
WO (1) WO2000053191A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
WO2003088961A1 (fr) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composes beta-agonistes contenant des groupes donneurs d'oxyde nitrique et des groupes piegeurs d'especes d'oxygene reactifs et leur utilisation dans le traitement de troubles respiratoires
WO2007088050A2 (fr) * 2006-02-03 2007-08-09 San Raffaele Centro Fond Procédé de traitement de la dystrophie musculaire
PL1978947T3 (pl) 2006-02-03 2015-03-31 Nicox Science Ireland Nitrooksypochodne do zastosowania w leczeniu dystrofii mięśniowych
WO2010108843A1 (fr) 2009-03-27 2010-09-30 Nicox S.A. Utilisation d'un dérivé nitro-oxy du paracétamol pour le traitement de dystrophies musculaires

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1997033173A1 (fr) * 1996-03-08 1997-09-12 The Regents Of The University Of California Traitement et diagnostic de la dystrophie musculaire, de l'ictus et d'autres maladies neurodegeneratives
JPH10120654A (ja) * 1996-10-17 1998-05-12 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583101A (en) * 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
WO1997033173A1 (fr) * 1996-03-08 1997-09-12 The Regents Of The University Of California Traitement et diagnostic de la dystrophie musculaire, de l'ictus et d'autres maladies neurodegeneratives
JPH10120654A (ja) * 1996-10-17 1998-05-12 Ono Pharmaceut Co Ltd 一酸化窒素合成酵素阻害剤

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AZZENA G B ET AL: "NITRIC OXIDE REGENERATES THE NORMAL COLONIC PERISTALTIC ACTIVITY IN MDX DYSTROPHIC MOUSE", NEUROSCIENCE LETTERS,LIMERICK,IE, vol. 261, no. 1/02, 1999, pages 9 - 12, XP000879028, ISSN: 0304-3940 *
AZZENA GIAN BATTISTA ET AL: "Nitric oxide regenerates the normal colonic peristaltic activity in mdx dystrophic mouse.", NEUROSCIENCE LETTERS, vol. 261, no. 1-2, 12 February 1999 (1999-02-12), pages 9 - 12, XP000961771, ISSN: 0304-3940 *
BREDT DAVID S: "NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 25, December 1998 (1998-12-01), Dec., 1998, pages 14592 - 14593, XP000960480, ISSN: 0027-8424 *
CHAO DANIEL S ET AL: "Selective loss of sarcolemmal nitric oxide synthase in becker muscular dystrophy.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 2, 1996, pages 609 - 618, XP000961763, ISSN: 0022-1007 *
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C PHARMACOLOGY TOXICOLOGY &, vol. 118, no. 3, November 1997 (1997-11-01), Nov., 1997, pages 375 - 379, ISSN: 0742-8413 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, BAEK MI-YEONG ET AL: "Changes in the cellular cGMp levels and guanylate cyclase activities during chick myoblast fusion.", XP002154299, Database accession no. PREV199396097003 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 1997 (1997-11-01), LAMOSOVA D ET AL: "Influence of melatonin on chick skeletal muscle cell growth.", XP002154300, Database accession no. PREV199800098087 *
DATABASE WPI Section Ch Week 199831, Derwent World Patents Index; Class B03, AN 1998-350696, XP002154301 *
EL-DADA, MANAR D. ET AL: "Involvement of nitric oxide in nicotinic receptor-mediated myopathy", J. PHARMACOL. EXP. THER. (1997), 281(3), 1463-1470, XP000972194 *
HAYCOCK J W ET AL: "OXIDATIVE DAMAGE TO MUSCLE PROTEIN IN DUCHENNE MUSCULAR DYSTROPHY", NEUROREPORT,GB,RAPID COMMUNICATIONS OF OXFORD, OXFORD, vol. 8, no. 1, 1996, pages 357 - 361, XP000879014, ISSN: 0959-4965 *
KALIMAN, PERLA ET AL: "Insulin-like growth factor-II, phosphatidylinositol 3-kinase, nuclear factor-.kappa.B and inducible nitric-oxide synthase define a common myogenic signaling pathway", J. BIOL. CHEM. (1999), 274(25), 17437-17444, XP000960874 *
KOREAN JOURNAL OF ZOOLOGY, vol. 36, no. 3, 1993, pages 433 - 438, ISSN: 0440-2510 *
LEE KUN HO ET AL: "Nitric oxide as a messenger molecular for myoblast fusion.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 20, 1994, pages 14371 - 14374, XP002154298, ISSN: 0021-9258 *
SARKAR RAJABRATA ET AL: "Nitric oxide inhibition of endothelial cell mitogenesis and proliferation.", SURGERY (ST LOUIS), vol. 118, no. 2, 1995, pages 274 - 279, XP000961764, ISSN: 0039-6060 *
SOHN YOON K ET AL: "Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases.", JOURNAL OF THE NEUROLOGICAL SCIENCES, vol. 162, no. 2, 15 January 1999 (1999-01-15), pages 133 - 151, XP000961766, ISSN: 0022-510X *
ULIBARRI J A ET AL: "Nitric oxide stimulates myoblast proliferation in vitro.", MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, vol. 29, no. 5 SUPPL., 1997, 44th Annual Meeting of the American College of Sports Medicine;Denver, Colorado, USA; May 28-31, 1997, pages S228, XP000961780, ISSN: 0195-9131 *
YAN ZHONG-QUN ET AL: "Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells.", CIRCULATION RESEARCH, vol. 82, no. 1, pages 21 - 29, XP000961767, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
WO2000053191A2 (fr) 2000-09-14
CA2371927A1 (fr) 2000-09-14
AU3139500A (en) 2000-09-28

Similar Documents

Publication Publication Date Title
AU5401900A (en) Coating method and coating mixture
EP1690534A3 (fr) Acide lipoique en compositions à usage local
HUP0001454A2 (en) Compositions and methods for treating plants with exogenous chemicals
DE69734766D1 (de) Hemmstoff und stimulator der proliferation haematopoietischer stammzellen und deren anwendungen
WO2004038000A3 (fr) Procedes d'utilisation de composes tetracycline substituee pour moduler l'arn
GB2421837A (en) Generating sets of tailored laser pulses
IE39120L (en) Dentifrices
MY121627A (en) Progesterone for treating or reducing ischemia
MY127021A (en) System and method for maintenance charging of battery cells
CA2404810A1 (fr) Composition topique contenant des cellules de graines d'erable
NO994309L (no) Fremgangsmaater for undertrykkelse av tumorvekst med kombinasjoner av isoprenoider og statiner
WO2000053191A3 (fr) Modulation de l'activation du precurseur du muscle squelettique
CA2242394A1 (fr) Procede de reduction du volume total d'acide contenu dans le petrole brut
AU2003247812A1 (en) Tool apparatus, system and method of use
HK1072010A1 (en) Topical dapsone for the treatment of acne
Fontecave et al. Reduction of the Fe (III)-tyrosyl radical center of Escherichia coli ribonucleotide reductase by dithiothreitol.
AU2668800A (en) Mixture of plant-treatment agents and waxes, method for producing same and the use thereof
EP0344572A3 (fr) Association d'un inhibiteur de l'enzyme de conversion de l'angiotensine avec un modulateur des canaux calcium et leurs utilisations comme médicaments
IE830664L (en) Treating acne
NZ330300A (en) Treating metal with a polyelectrolyte prior to or simultaneously with formation of a synthetic zeolite used to coat the metal
AU2003240275A1 (en) Method to improve adhesion of primers to substrates
FI100256B (fi) Menetelmä yhteentarttumisen estämiseksi teräsnauhaa hehkutettaessa
EP0361434A3 (fr) Système d'émulation d'affichage
FI946189A0 (fi) 5-alfa-reduktaasi-inhibiittoreina käyttökelpoiset 17-alkyyliketonisteroidit
JPS52150940A (en) Driving system for gas discharge panel

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371927

Country of ref document: CA

Kind code of ref document: A

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09936609

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载